According to Pradeep Bhandari of Sanofi, AI has proven its value in drug discovery by compressing the search for new drug molecules from a years-long process to a months-long process.

Sanofi is working with Everpure for foundational data and AI infrastructure in its labs and manufacturing sites.

Sanofi is building on-premise AI infrastructure to use open-source models, which mitigates costs by shifting from cloud token consumption to primarily paying for electricity.

Sanofi is starting to see real payoffs from its AI initiatives, resulting in a faster "time to science."